213 related articles for article (PubMed ID: 8990355)
1. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
[TBL] [Abstract][Full Text] [Related]
2. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
International Neoral Renal Transplantation Study Group.
Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
5. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
Internation Neoral Renal Transplantation Study Group
Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.
Cole E; Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffrey J; Russell D; Stiller C; Muirhead N; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P; Tan A; Hendricks L
Transplantation; 1998 Feb; 65(4):505-10. PubMed ID: 9500624
[TBL] [Abstract][Full Text] [Related]
8. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
9. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
[TBL] [Abstract][Full Text] [Related]
11. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
[TBL] [Abstract][Full Text] [Related]
12. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
13. Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra.
Terrill CJ; Lill J; Somerville KT; Sherbotie JR
J Ren Nutr; 2003 Jan; 13(1):26-30. PubMed ID: 12563620
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
[TBL] [Abstract][Full Text] [Related]
16. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients.
Cheung CY; Wong KM; Chan HW; Liu YL; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Li CS
Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.
Kovarik JM; Mueller EA; van Bree JB; Flückiger SS; Lange H; Schmidt B; Boesken WH; Lison AE; Kutz K
Transplantation; 1994 Sep; 58(6):658-63. PubMed ID: 7940685
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
19. The effect of two different cyclosporine formulations on the long-term progression to chronic rejection in renal allograft recipients.
Goel M; Flechner SM; Ischikawa A; Induhara R; Mastroianni B; Savas K; Modlin C; Goldfarb D; Feng J; Cook DJ; Novick AC
Clin Transplant; 2002 Dec; 16(6):442-9. PubMed ID: 12437625
[TBL] [Abstract][Full Text] [Related]
20. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
